Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.

Paz RD, Tardito S, Atzori M, Tseng KY.

Eur Neuropsychopharmacol. 2008 Nov;18(11):773-86. doi: 10.1016/j.euroneuro.2008.06.005. Review.

2.
3.
4.

Novel pharmacological approaches to the treatment of schizophrenia.

Fink-Jensen A.

Dan Med Bull. 2000 Jun;47(3):151-67. Review.

PMID:
10913983
5.

Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.

Heresco-Levy U.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1113-23. Review.

PMID:
14642971
6.

Glutamatergic theories of schizophrenia.

Javitt DC.

Isr J Psychiatry Relat Sci. 2010;47(1):4-16. Review.

7.

Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.

de Bartolomeis A, Fiore G, Iasevoli F.

Curr Pharm Des. 2005;11(27):3561-94. Review.

PMID:
16248808
8.

Model-based parametric study of frontostriatal abnormalities in schizophrenia patients.

Tanaka S.

BMC Psychiatry. 2010 Feb 27;10:17. doi: 10.1186/1471-244X-10-17. Erratum in: BMC Psychiatry. 2010;10:93.

9.

Glutamatergic drugs for schizophrenia treatment.

Gibert-Rahola J, Villena-Rodriguez A.

Actas Esp Psiquiatr. 2014 Sep-Oct;42(5):234-41.

10.

The potential role of lamotrigine in schizophrenia.

Large CH, Webster EL, Goff DC.

Psychopharmacology (Berl). 2005 Sep;181(3):415-36. Review.

PMID:
16001126
11.

[Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].

Pannese R, Minichino A, Pignatelli M, Delle Chiaie R, Biondi M, Nicoletti F.

Riv Psichiatr. 2012 Mar-Apr;47(2):149-69. doi: 10.1708/1069.11719. Review. Italian.

PMID:
22622251
12.
13.

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

Goff DC, Coyle JT.

Am J Psychiatry. 2001 Sep;158(9):1367-77. Review.

PMID:
11532718
14.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

15.

[Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].

Kolomeets NS.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(1):110-7. Review. Russian.

PMID:
25945378
16.

Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA.

Curr Top Med Chem. 2013;13(1):26-54. Review.

17.

Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia.

Deakin FW, Simpson MD, Slater P, Hellewell JS.

J Psychopharmacol. 1997;11(2):133-42. Review.

PMID:
9254279
18.

Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.

Heresco-Levy U.

Expert Opin Emerg Drugs. 2005 Nov;10(4):827-44. Review.

PMID:
16262565
19.
20.

Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.

Amargós-Bosch M, Adell A, Artigas F.

J Neurochem. 2007 Jul;102(2):550-61.

Items per page

Supplemental Content

Support Center